Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London flag London · Delayed Price · Currency is GBP · Price in USD
708.66
0.00 (0.00%)
At close: Dec 23, 2024

Regeneron Pharmaceuticals Company Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc.
Country United States
Founded 1988
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 13,450
CEO Leonard Schleifer

Contact Details

Address:
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
United States
Phone 914 847 7000
Website regeneron.com

Stock Details

Ticker Symbol 0R2M
Exchange London Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number US75886F1075
SIC Code 2834

Key Executives

Name Position
Leonard Schleifer Chief Executive Officer
Christopher Fenimore Chief Financial Officer
Patrice Gilooly Chief Operating Officer
Ryan Crowe Head of Investor Relations